Fecal Calprotectin and RT-PCR from both nasopharyngeal swab and stool samples prior to treatment decision in IBD patients during CoVID-19 outbreak.

It is with great interest that I read the publication of F. Zingone et al. recommending screening for active coronavirus disease 2019 infection (CoVID-19) and immunization status prior to biologic therapy in inflammatory bowel disease (IBD) patients at the time of the pandemic outbreak [1]. As the authors suggest, the screening of CoVID-19 positive cases is mandatory in the management of IBD patients even when presenting symptoms are exclusively digestive. However, the screening should not be limited to swab or throat samples.

Source: Digestive and Liver Disease - May 28, 2020 Category: Gastroenterology Authors: Dr Cherradi Younes Tags: Correspondence Source Type: research